Phillip Minar

Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn’s Disease in Treatment-Naive Pediatric Patients

Michael J. Rosen, Rebekah Karns, Jefferson E. Vallance et al. · Gastroenterology · 2017 · 69 citations · Full text

Inflammation, Type 17, Allergy +11

Real‐World Infliximab Pharmacokinetic Study Informs an Electronic Health Record‐Embedded Dashboard to Guide Precision Dosing in Children with Crohn’s Disease

Ye Xiong, Tomoyuki Mizuno, Ruben J. Colman et al. · Clinical Pharmacology & Therapeutics · 2020 · 68 citations · Full text

Gastroenterology, Pharmacotherapy, Physiologically-based Pharmacokinetic Modeling +22

Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients

Kathryn Clarkston, Yi‐Ting Tsai, Kimberly Jackson et al. · Journal of Pediatric Gastroenterology and Nutrition · 2019 · 63 citations · Full text

IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function

Amanda Waddell, Jefferson E. Vallance, Preston D. Moore et al. · Inflammatory Bowel Diseases · 2015 · 55 citations · Full text

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

John L. Lyles, Aditi Mulgund, Laura E. Bauman et al. · Inflammatory Bowel Diseases · 2020 · 51 citations · Full text